Animal Models of T Cell Mediated Skin Diseases

Nevertheless, attrition rates in clinical development are still very high, and up to 90% of new compounds fail in clinical phase I - III trials, which is partially due to lack of clinical efficacy. Such animal models should have impact not only on inflammatory dermatoses but also on other inflammatory disorders due to their model character. Pharmaceutical companies are spending increasing amounts of money on drug discovery and development. Nevertheless, attrition rates in clinical development are still very high, and up to 90% of new compounds fail in clinical phase I - III trials, which is partially due to lack of clinical efficacy. This indicates a strong need for highly predictive in vitro and in vivo models. The "50th International Workshop of the Ernst Schering Research Foundation" focussed on "Animal Models of T Cell-Mediated Skin Diseases". Such animal models should have impact not only on inflammatory dermatoses but also on other inflammatory disorders due to their model character. The current volume summarises recent advances in animal research that are important for anti-inflammatory drug discovery.

Nevertheless, attrition rates in clinical development are still very high, and up to 90% of new compounds fail in clinical phase I - III trials, which is partially due to lack of clinical efficacy. Such animal models should have impact not only on inflammatory dermatoses but also on other inflammatory disorders due to their model character.